Bayer Aktiengesellschaft (LON:0P6S)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 40.29B +69.5% |
| Revenue (ttm) | 39.07B -1.7% |
| Net Income | -1.50B |
| EPS | -1.52 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.24 |
| Dividend | 0.10 (0.25%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 654,797 |
| Open | 47.34 |
| Previous Close | 47.92 |
| Day's Range | 45.40 - 47.45 |
| 52-Week Range | 25.79 - 54.00 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer faces trial test of remaining Roundup claims after US Supreme Court win
Attorneys for three cancer patients told a Missouri jury on Tuesday that Bayer's Monsanto unit failed to adequately test its Roundup weedkiller before selling it, starting a trial that could help de...
MiraSOFT Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
Bayer today announced the launch of MiraSOFT, a new stool softener option from the makers of MiraLAX with the active ingredient docusate sodium designed to help gently soften hard, dry stools and supp...
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests to dismiss patent lawsuits filed against them by Bayer's Monsanto unit over the messenger RNA technology used in...
Bayer Gains FDA Priority Review For Lynkuet Label Expansion In Breast Cancer-Related Indication
(RTTNews) - Bayer Aktiengesellschaft (BAYN.DE) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Revie...
Bayer: FDA Grants Priority Review To Lynkuet For New Indication
(RTTNews) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has accepted the supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation for the treatmen...
Bayer announces FDA accepts Lynkuet sNDA for Priority Review
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation ...
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer's Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer to sell cancer drug Stigvarga for up to $431M, WSJ reports
Bayer (BAYRY) has agreed to sell the rights to its cancer drug Stivarga to Gruenenthal Group for up to EUR 375M, or $431M, The Wall Street Journal’s Adria Calatayud reports.
Bayer Sells Stivarga Rights to Gruenenthal for Up to €375 Million
Bayer Sells Stivarga Rights to Gruenenthal for Up to €375 Million
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
US environment agency let Bayer pick regulations for destructive weedkiller, documents show
Environmental Protection Agency asked firm to choose rules it wanted for dicamba, then put the choices in a proposed federal rule The EPA allowed pesticide giant Bayer to pick from a menu of regulatio...
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
EQS-PVR: Bayer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribu...
Robigo announces Series A funding led by Leaps by Bayer
Robigo announced a Series A funding led by Leaps by Bayer (BAYRY) with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial lau...
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with par...
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and ...
Bayer's Kerendia Wins FDA Approval As First New CKD Treatment For Type 1 Diabetes In 30 Years
(RTTNews) - Bayer AG (BAYRY) announced that the U.S. FDA has approved Kerendia as the first new treatment in more than three decades for adults with chronic kidney disease (CKD) associated with type 1...
Bayer: FDA Approves Kerendia To Treat Chronic Kidney Disease Associated With Type 1 Diabetes
(RTTNews) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has approved Kerendia or finerenone for the treatment of adult patients with chronic kidney disease associated with type 1 diabetes. The ap...
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UAC...
Bayer’s KERENDIA (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce th...
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to...
Bayer faces pivotal test of US$7.25 billion Roundup settlement in Missouri court
Bayer’s Monsanto unit seeks approval of a US$7.25 billion settlement to resolve lawsuits alleging that its popular weedkiller Roundup causes cancer.
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkill...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a criti...